fbpx

EMERGERS

Equity Research of
Nordic Growth Companies

HomeAnalys

Analys

QLUCORE: Important milestone passed on the road to a more individualized cancer care

2023-03-02• Analys, Research

The progress in Q3’22/23 (Nov–Jan) continues to support the long term case we’re seeing in Qlucore, where the company aims to provide...

Read More →

Video Interview | KEBNI: Targeting capacity of 10,000 IMUs per year in 2025

2023-03-02• Analys, Research

With another NLAW order to Saab from Finland of SEK 400m, KebNi is now targeting a production capacity of 10,000 IMUs by 2025 and expect...

Read More →

Interview | CRUNCHFISH: ”Simultaneous expansion of potential, presence, people, product and patent portfolio”

2023-03-01• Analys, Research

On its mission to provide the same level of robustness to digital payments services as is required by other commercial and public goods...

Read More →

BONZUN: Evolve to drive doubling of revenues in 2023

2023-02-27• Analys, Research

After a comprehensive adjustment of business focus, balance sheet, costs and valuation in 2022, along with a recent restocking of the...

Read More →

KEBNI: Great NLAW backdrop yet to translate to the KebNi share

2023-02-27• Analys, Research

With another NLAW order, from Finland of SEK 400m, Saab’s delivery timeline support a revenue scenario for KebNi that exceeds its own...

Read More →

MOTION DISPLAY: Strong start to 2023 sets the stage for an exciting year ahead

2023-02-24• Analys, Research

As 2022 ended on a high note for Motion Display, with deals signed in the USA, Germany and Australia, there are reasons to believe that...

Read More →

FREE2MOVE: Targets profitable growth as energy efficiency is rising on the agenda

2023-02-21• Analys, Research

With a comprehensive offering to drastically improve the operating net for property owners, Free2Move looks to continue its strong growth...

Read More →

SIMRIS ALG: Transforming to build an integrated multi-vertical microalgae and cyanobacteria company  

2023-02-20• Analys, Research

Simris’ expanded objective to leverage the acquisition of Cyano Biotech in Q3’22, enter the high-value biopharma space and build a...

Read More →

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

2023-02-17• Analys, Research

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two...

Read More →

AGTIRA: Looking to maintain momentum into 2023

2023-02-15• Analys, Research

Agtira closed its books for 2022 reaching record high sales of 25.5 MSEK, an 80% increase compared to 2021. While the growth was strong, we...

Read More →

For the best ETF trading and investment ideas

ActionETFs.com

CONTACT

Johan Widmark

Mail: johan@emergers.se
Tel: +46739196641

Östermalmsgatan 26A
114 26 Stockholm, Sweden

For new research on growth stocks, sign up to our newsletter